Growth Drivers: Factors fueling market expansion include the growing geriatric demographic, governmental attention to eye care policies, escalating diabetes rates globally, enhanced access to ...

Colombia's growing middle class is driving demand for advanced ophthalmic devices, leading to a surge in market opportunities for medical technology companies.

Latanoprost SR is under clinical development by Peregrine Ophthalmic and currently in Phase I for Unspecified Ophthalmological Disorders.

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging ...

06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its ...

22, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today provided an update on its ongoing restructuring efforts. The Company announced today that Avenue ...

Our growth has driven our practices’ technical requirements and increased the complexity of managing disparate clinical operations across multiple systems,” said Kurt Williams, CEO at Eye Care ...

Beacon Therapeutics has raised $170m in a Series B funding round to accelerate the development of its lead asset AGTC-501, for X-linked retinitis pigmentosa (XLRP). The financing round was led by ...